Theriva Biologics (TOVX) traded up 5.26 % during a 24 hours period ending at 03:53 PM Central Europe on Monday 26th. One Theriva Biologics stock can currently be bought for about USD 0.19 on popular exchanges. Current supply of Theriva Biologics stocks is 45.9 mn. Theriva Biologics has a current market capitalization of USD 9 mn and approximately USD 86 k worth of Theriva Biologics was traded on exchanges in the last 24 hours. Since last month end, Theriva Biologics has traded -13.04 % down. Simple moving average of last 200 days is at USD 0.24. The highest price of past 52 weeks was recorded at USD 0.49 on 04/20/2026. 52 weeks low was at USD 0.16 on 02/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Intensity Therapeutics (INTS) traded up 1.88 % and now trades at USD 3.24. Current market capitalisation for Intensity Therapeutics is USD 10.6 mn.

  • Netcapital (NCPL) traded down -40.36 % and now trades at USD 1.4. Current market capitalisation for Netcapital is USD 10.7 mn.

  • Ten (XHLD) traded up 7.71 % and now trades at USD 0.85. Current market capitalisation for Ten is USD 10.2 mn.

  • Astrotech (ASTC) traded down -0.4 % and now trades at USD 5.03. Current market capitalisation for Astrotech is USD 10.3 mn. ASTROTECH CORP has announced a series of corporate actions that include a formal name change and a change of ticker symbol on the Australian Securities Exchange. The transition, approved at the latest annual general meeting, will see the company rebrand and adopt a new listing code effective from the start of trading on 2 November 2026. The change is part of a broader effort to align the company’s identity with its evolving business strategy. Shareholders were informed that no action is required on their part, as the updates will be processed automatically. The announcement also highlighted that the company’s corporate structure and principal operations remain unchanged, and that the rebranding is supported by the Australian Securities and Investments Commission.

  • In8bio (INAB) traded up 6.49 % and now trades at USD 0.97. In8bio has a market capitalisation of USD 10.4 mn.

About Theriva Biologics

Theriva Biologics, Inc. is a biotech company that specializes in developing an adenovirus platform for intravenous (IV), intravitreal, and antitumoral delivery. This platform is designed to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The company operates out of Rockville, United States, in the health care sector, with a focus on biotechnology as their industry. Their website is www.therivabio.com , and they are listed on the New York Stock Exchange. Their IPO date was June 26, 2006.